WO2013045591A3 - Procédé et kit pour le diagnostic in vitro du cancer du sein - Google Patents

Procédé et kit pour le diagnostic in vitro du cancer du sein Download PDF

Info

Publication number
WO2013045591A3
WO2013045591A3 PCT/EP2012/069150 EP2012069150W WO2013045591A3 WO 2013045591 A3 WO2013045591 A3 WO 2013045591A3 EP 2012069150 W EP2012069150 W EP 2012069150W WO 2013045591 A3 WO2013045591 A3 WO 2013045591A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit
breast cancer
vitro diagnosis
ruvbl1
phb2
Prior art date
Application number
PCT/EP2012/069150
Other languages
English (en)
Other versions
WO2013045591A2 (fr
Inventor
Jérôme SOLASSOL
Alain MANGE
Thierry MAUDELONDE
Jérôme LACOMBE
Philippe Rouanet
Original Assignee
Ctre Hosp Universitaire De Montpellier
Centre Regional Lutte Contre Le Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctre Hosp Universitaire De Montpellier, Centre Regional Lutte Contre Le Cancer filed Critical Ctre Hosp Universitaire De Montpellier
Publication of WO2013045591A2 publication Critical patent/WO2013045591A2/fr
Publication of WO2013045591A3 publication Critical patent/WO2013045591A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de diagnostic in vitro du cancer du sein chez un individu, comprenant la détection, dans un échantillon biologique issu dudit individu, d'au moins un auto-anticorps dirigé contre une protéine parmi l'ensemble comprenant PAK2, PHB2, RUVBL1, RACK1 et GAL3. Un kit pour la mise en œuvre d'un tel procédé comporte au moins une protéine parmi l'ensemble comprenant PAK2, PHB2, RUVBL1, RACK1 et GAL3.
PCT/EP2012/069150 2011-09-28 2012-09-27 Procédé et kit pour le diagnostic in vitro du cancer du sein WO2013045591A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1158714 2011-09-28
FR1158714A FR2980578B1 (fr) 2011-09-28 2011-09-28 Procede et kit pour le diagnostic in vitro du cancer du sein
FR1256359 2012-07-03
FR1256359A FR2980579B3 (fr) 2011-09-28 2012-07-03 Procede et kit pour le diagnostic in vitro du cancer du sein

Publications (2)

Publication Number Publication Date
WO2013045591A2 WO2013045591A2 (fr) 2013-04-04
WO2013045591A3 true WO2013045591A3 (fr) 2013-06-20

Family

ID=45592506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/069150 WO2013045591A2 (fr) 2011-09-28 2012-09-27 Procédé et kit pour le diagnostic in vitro du cancer du sein

Country Status (2)

Country Link
FR (2) FR2980578B1 (fr)
WO (1) WO2013045591A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094876A1 (fr) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Diagnostic et traitements des maladies associees a la kinase activee par p21 (cdkn1a) (pak2)
WO2011109663A1 (fr) * 2010-03-03 2011-09-09 Nox Technologies, Inc. Auto-anticorps spécifiques d'une néoplasie et méthodes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094876A1 (fr) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Diagnostic et traitements des maladies associees a la kinase activee par p21 (cdkn1a) (pak2)
WO2011109663A1 (fr) * 2010-03-03 2011-09-09 Nox Technologies, Inc. Auto-anticorps spécifiques d'une néoplasie et méthodes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSON K.S. ET AL.: "Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer", J. PROTEOME RES., vol. 10, no. 1, 7 January 2011 (2011-01-07), pages 85 - 96, XP055048275 *
DESMETZ C. ET AL.: "Autoantibody signatures: progress and perspectives for early cancer detection", J. CELL. MOL. MED., vol. 15, no. 10, 26 September 2011 (2011-09-26), pages 2013 - 2024, XP055024525 *
DESMETZ C. ET AL.: "Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women", CLIN. CANCER RES., vol. 15, no. 14, 15 July 2009 (2009-07-15), pages 4733 - 4741, XP008145040 *
LACOMBE J. ET AL.: "Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers", INT. J. CANCER, vol. 00, no. 00, 7 August 2012 (2012-08-07), pages 1 - 9, XP002689618, DOI: 10.1002/ijc.27766 *
MANGÉ A. ET AL.: "Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer", CLIN. CANCER RES., vol. 18, no. 7, 1 April 2012 (2012-04-01), pages 1992 - 2000, XP002689617 *

Also Published As

Publication number Publication date
FR2980578A1 (fr) 2013-03-29
FR2980579B3 (fr) 2014-01-17
FR2980579A3 (fr) 2013-03-29
FR2980578B1 (fr) 2013-09-27
WO2013045591A2 (fr) 2013-04-04

Similar Documents

Publication Publication Date Title
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
EP3054299A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
WO2013040142A3 (fr) Procédés bio-informatiques de détermination de liaisons peptidiques
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
IL232219B (en) Human or humanized antibodies against tar-dna-binding protein 43kda and their uses
WO2014107599A3 (fr) Compositions et procédés de détection d'une activité protéase dans des systèmes biologiques
WO2012054638A3 (fr) Systèmes et procédés nmr pour la détection d'analytes
WO2012009644A3 (fr) Procédés pour identifier des éléments d'arn synthétiques et naturels qui améliorent la traduction des protéines
WO2012048340A3 (fr) Séquençage immunitaire à haut débit
IL222252A (en) A system, device and method for detecting and diagnosing biological arrhythmias
WO2012056457A3 (fr) COMPOSITIONS ET PROCÉDÉS D'ACTIVATION D'EXPRESSION PAR UN ARNmi ENDOGÈNE SPÉCIFIQUE
EP3683320A3 (fr) Empreinte arnmi dans le diagnostic de cancer du poumon
EP2542581A4 (fr) Anticorps spécifique d'apolipoprotéine, et procédés d'utilisation correspondant
WO2013022786A3 (fr) Biomarqueurs micro-arn
WO2011135194A3 (fr) Procédé pour diagnostiquer un risque de diabète de type 1 et prévenir le déclenchement d'un diabète de type 1
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
WO2012083969A3 (fr) Microarn pour le diagnostic du cancer du pancréas
WO2011088385A3 (fr) Compositions et procédés pour la détection du cancer
WO2012094550A3 (fr) Essais et procédés de traitement associés à une carence en vitamine d
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
WO2011106541A3 (fr) Méthodes de diagnostic impliquant une perte d'hétérozygosité
WO2012058220A3 (fr) Anticorps anti-sod1 et utilisations de ceux-ci
WO2012052994A3 (fr) Marqueurs de dysfonctionnement primaire du greffon
WO2011119986A3 (fr) Procédés de culture et d'analyse de cellules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12762639

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12762639

Country of ref document: EP

Kind code of ref document: A2